Article
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Rating:
0.0
Views:
58
Likes:
1
Library:
1
Bristol Myers Squibb has received a March 27 PDUFA date for its anti-BCMA CAR-T cell therapy. The priority review action date sets Bristol Myers up to win approval for the bluebird bio-partnered drug in time to satisfy the terms of its acquisition of Celgene.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value